ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder CancerBusiness Wire · 3 days ago
ImmunityBio Study Shows Long-Term Success for Bladder Cancer TreatmentBenzinga · 5 days ago
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary TumorsBusiness Wire · Oct 16, 2026
FDA Expands ImmunityBio's Anktiva Label in Bladder CancerZacks Investment Research · Oct 15, 2026
ImmunityBio Stock Climbs Thursday: What's Going On?Benzinga · Oct 15, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS DiseaseBusiness Wire · Oct 14, 2026ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.08 | -$0.22 | Miss |
| May 7, 2026 | -$0.08 | -$0.62 | Miss |
| Feb 23, 2026 | -$0.08 | -$0.06 | Beat |
| Nov 4, 2025 | -$0.10 | -$0.07 | Beat |
| Aug 5, 2025 | -$0.10 | -$0.10 | Beat |
| May 12, 2025 | -$0.12 | -$0.15 | Miss |